Skip to main content
Vivoryon Therapeutics N.V. logo

Vivoryon Therapeutics N.V. — Investor Relations & Filings

Ticker · VVY ISIN · NL00150002Q7 LEI · 3912004AMB0KGZXZYJ15 AS Manufacturing
Open in API
Filings indexed 400 across all filing types
Latest filing 2023-08-31 Report Publication Anno…
Country NL Netherlands
Listing AS VVY

About Vivoryon Therapeutics N.V.

https://www.vivoryon.com/

Vivoryon Therapeutics N.V. is a clinical-stage precision medicine company focused on developing first-in-class therapies by targeting post-translational modifications of proteins. The company's scientific approach centers on inhibiting glutaminyl cyclases (QPCT and QPCTL), enzymes that catalyze pyroglutamate formation, a process implicated in the progression of various diseases. Its lead product candidate, varoglutamstat, is an orally administered small molecule QPCT/L inhibitor. Vivoryon is advancing its therapeutic pipeline for patients with inflammatory, fibrotic, and neurodegenerative diseases, with a strategic focus on conditions such as chronic kidney disease.

Recent filings

Filing Released Lang Actions
Vivoryon Therapeutics N.V. to Report Half Year 2023 Financial Results and Operational Progress on September 07, 2023
Report Publication Announcement Classification · 99% confidence The document is a press release announcing that Vivoryon Therapeutics N.V. will report its 'Half Year 2023 Financial Results and Operational Progress' on September 07, 2023. It details the date, time, and method for accessing the subsequent conference call and webcast where the results will be discussed. Crucially, the document itself is not the financial report (which would be an IR or ER), but rather an announcement *about* the upcoming release of those results. According to Rule 2, when a document announces the publication of a report and provides details for an associated event (like a call), it fits the definition of a Report Publication Announcement (RPA). The document length (5521 chars) is consistent with a short announcement rather than a full financial filing.
2023-08-31 English
Vivoryon Therapeutics N.V. Announces Proposed Appointment of Dr. Frank Weber as Chief Executive Officer
Board/Management Information Classification · 99% confidence The document is a press release announcing significant changes in senior management: the proposed appointment of Dr. Frank Weber as CEO and Anne Doering as CS&IRO. It details the transition, the rationale behind the appointments, and provides background on the incoming and outgoing executives. This content directly aligns with the definition of 'Board/Management Information' (MANG), which covers announcements of changes in the company's board of directors or senior management.
2023-08-07 English
Vivoryon Therapeutics N.V. Extraordinary General Meeting to Confirm New Executive Director Appointments to the Board, Being Held on September 15, 2023
AGM Information Classification · 98% confidence The document explicitly announces an 'Extraordinary General Meeting (EGM)' scheduled for September 15, 2023, with the primary agenda item being the confirmation of new Executive Director appointments to the Board. This content directly relates to shareholder meetings and board composition changes. The most fitting category is 'AGM Information' (AGM-R), as EGMs are a form of general meeting, and the material is directly related to the meeting's purpose and agenda, which includes board appointments. While 'Board/Management Information' (MANG) is relevant due to the director appointments, the context is framed entirely around the upcoming shareholder meeting where these changes will be formalized, making AGM-R the primary classification.
2023-08-07 English
Vivoryon Therapeutics N.V. Shares Clinical Development Update Highlighting Progress of N3pE-Amyloid-targeting Small Molecule Varoglutamstat in Alzheimer’s Disease
Earnings Release Classification · 95% confidence The document is a press release dated July 16, 2023, providing a 'Clinical Development Update' on the progress of the drug varoglutamstat in Alzheimer's disease. It details results from ongoing Phase 2 studies (VIVIAD and VIVA-MIND), mentions data presented at a conference (AAIC 2023), and provides timelines for future data readouts (Q1/2024). This content structure—a summary of recent operational and clinical progress, often released outside of mandatory quarterly/annual filings—is characteristic of an Earnings Release (ER) or a general corporate update. Since it focuses on clinical trial progress and operational milestones rather than comprehensive financial statements (like a 10-K or IR), and it is an announcement of recent developments, it fits best under the Earnings Release (ER) category, which typically covers key operational highlights for a period. It is not a full transcript (CT), a formal annual report (10-K), or a specific regulatory filing announcement (RPA/RNS) announcing the publication of a different document. H1 2023
2023-07-17 English
Vivoryon Therapeutics N.V. Reports Outcome of 2023 Annual General Meeting
AGM Information Classification · 100% confidence The document is explicitly titled "Vivoryon Therapeutics N.V. Reports Outcome of 2023 Annual General Meeting". It details that all proposed resolutions were approved and announces the election of new Non-Executive Board members following the AGM held on June 21, 2023. This content directly relates to the proceedings and outcomes of the Annual General Meeting. Therefore, the appropriate classification is AGM Information (AGM-R).
2023-06-22 English
Vivoryon Therapeutics N.V. Announces CEO Transition Plan
Board/Management Information Classification · 100% confidence The document is a press release dated June 15, 2023, announcing a transition plan for the CEO, Dr. Ulrich Dauer, who will step down after the 2024 Annual General Meeting (AGM). It details the Board's intention to initiate succession planning. This content directly relates to changes in senior management personnel. Based on the definitions, the most appropriate classification is 'Board/Management Information' (MANG). It is not an Earnings Release (ER), a Call Transcript (CT), or an AGM presentation itself (AGM-R), but rather an announcement *about* management succession.
2023-06-16 English

Browse filings by year

13 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.